A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-07976016 AND PF-06882961 IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY
Latest Information Update: 20 Jun 2025
At a glance
- Drugs Danuglipron (Primary) ; PF 07976016 (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 15 Jun 2025 According to a ClincalTrial.gov record, this study was discontinued prior to PF-06882961 administration.
- 04 May 2025 Planned End Date changed from 5 Aug 2025 to 20 May 2025.
- 04 May 2025 Planned primary completion date changed from 5 Aug 2025 to 20 May 2025.